Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Greenwich LifeSciences (GLSI) Shares Outstanding (Diluted Average) (2022 - 2025)

Greenwich LifeSciences filings provide 4 years of Shares Outstanding (Diluted Average) readings, the most recent being $13.6 million for Q3 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 3.8% to $13.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Sep 2025, up 3.8% year-over-year, with the annual reading at $13.0 million for FY2024, 1.3% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $13.6 million in Q3 2025 for Greenwich LifeSciences, up from $13.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $13.6 million in Q3 2025 and bottomed at $12.8 million in Q3 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $13.0 million, with a median of $12.9 million recorded in 2022.
  • The largest annual shift saw Shares Outstanding (Diluted Average) dropped 0.58% in 2023 before it increased 3.8% in 2025.
  • Greenwich LifeSciences' Shares Outstanding (Diluted Average) stood at $12.9 million in 2022, then decreased by 0.51% to $12.8 million in 2023, then increased by 1.3% to $13.0 million in 2024, then grew by 4.82% to $13.6 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Shares Outstanding (Diluted Average) are $13.6 million (Q3 2025), $13.4 million (Q2 2025), and $13.2 million (Q1 2025).